Moleculin Biotech (MBRX)

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 12 Mar 2018 18:57

Ik heb een eerste positie genomen in MBRX.
Bedrijf heeft een relatief kleine OS onder 25 Mil en een FF onder 15 Mil.

https://ir.moleculin.com/financial-information

"Moleculin has three potential breakthrough disruptive technologies --

(1) Annamycin, an anticancer agent that is active against multidrug resistant tumor cells and has been designed to be non-cardio toxic (unlike currently approved drugs in this class),

(2) immuno-stimulating STAT3 inhibitors like WP1066 and, now, WP1732, and

(3) WP1122, a metabolic inhibitor that has been shown in preclinical testing to effectively block the energy supply required by cancer cells to function and proliferate. Since our IPO in June 2016, we have accelerated to the point of having two drugs, Annamycin and WP1066, beginning clinical trials in the near term."



Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 12 Mar 2018 20:55

Moleculin to Present at the 30th Annual ROTH Conference Tuesday, March 13, 2018

HOUSTON, TX -- (Marketwired) -- 03/06/18 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that Walter Klemp, chief executive officer and Jon Foster, chief financial officer, will present at the 30th Annual ROTH Conference on Tuesday, March 13, 2018 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) in Yellow - Salon 6. The conference is being held at the Ritz-Carlton Hotel in Dana Point, California from March 11-14, 2018.

A webcast of the presentation will be available at the Investor Relations page of the Company's website at http://www.moleculin.com. The webcast and presentation will be archived on the Company's website for 90 days following the event.
The Company will also host investor meetings throughout the day on Tuesday, March 13, 2018. Attendance at the conference is by invitation only for clients of ROTH Capital Markets. Interested investors should contact your ROTH Capital Markets sales representative or Lytham Partners at (602) 889-9700 or mbrx@lythampartners.com to secure a meeting time.

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 13 Mar 2018 10:12

Exclusive: Moleculin CEO Says Acute Myeloid Leukemia Candidate Could Be 'Remarkable'

Oncological drug developers have fierce competition for patients, both in trials and in market. But Moleculin Biotech Inc (NASDAQ: MBRX) rests secure, snugly insulated from the battle.

“There’s a reason not a lot of people are playing in the sandbox we’re playing in,” Moleculin CEO Walter Klemp recently told Benzinga. “It’s hard. It’s really hard, and because there aren’t many people in these particular indications, that general competition for patients — we’re buffered from it.”

An Incidental Strategy
Moleculin targets hard-to-treat and rare diseases, with three properties addressing pancreatic cancer, melanoma, leukemia and glioblastoma. Competitors are so sparse “you almost can hear crickets," Klemp said.

The CEO considers the loneliness an advantage, compounding the expedited regulatory processes and cheaper trials afforded to orphan drug developers.

This wasn't always the plan. Moleculin launched in 2007 with a focused goal of developing its WP1066 for psoriasis. Just as the team was outgrowing its friend-and-family financing and began prepping for a June 2016 initial public offering, it was presented with an opportunity.

The developers of a drug called annamycin depleted their funding before completing a Phase 2 study and approached Klemp with an offer.

“We said, 'if we’re going to create a public company, [it's] far better that we create a public company that has a diverse portfolio' — what I call multiple shots on goal,” Klemp said. “... We intend to save lives and we’re pushing every button we know ... to do that.”

The Pipeline’s Potential
Moleculin is slowing its rate of project expansion and is instead devoting capital to its pipeline, particularly annamycin.

The treatment has the potential to outperform Vyxeos, an acute myeloid leukemia drug that extended the survival time of trial participants by about three-and-a-half months.

“We think we have the chance to more than double the number of patients [who] can qualify for a bone marrow transplant, which would just be remarkable [and] would be huge for the disease,” Klemp said.

Annamycin’s previous developers only dosed Phase 2a participants before exhausting funds, but anecdotal data summaries were nonetheless encouraging.

Of the eight near-death, option-expended patients who were dosed, five reported complete removal of AML from their blood, according to the Journal of Clinical Lymphoma, Myeloma and Leukemia.

Three were rid of bone marrow blasts, which qualified them for curative bone marrow transplants and provided an 80-percent chance of full recovery.

“Instead of talking about increasing overall survival by about three-and-a-half months, we’re talking about saving their lives,” Klemp said. “... If we’re right and able to reproduce that data in our own trials, I would argue that that would be a greater contribution to AML than Vyxeos was.”


“If three-and-a-half months is worth $1.5 billion, I can’t wait to see what annamycin might be able to accomplish,” Klemp said.

Clinical Progress
Moleculin is on “on the cusp” of initiating annamycin trials for AML in the U.S. and Poland, and Klemp said patient recruitment, a step expected to kick off this quarter, is “imminent.”

The Houston-based company also intends to launch two additional studies this year within the 700-molecule WP1066 portfolio. The namesake molecule has been approved as an Investigational New Drug and will begin a brain tumor trial before the end of the first half, while 1220 is expected to start clinicals for cutaneous T-cell lymphoma before the end of 2018.

Management also sees yet-unproven potential in the WP1732 candidate, whose preclinical test results suggested a "breakthrough" opportunity to treat pancreatic cancer through the ubiquitination process.

The WP1122 portfolio, an attempt to use metabolic inhibition to attack tumors, is in preclinical or IND-enabling development this year.

“What I hope people see when they look at our portfolio is sort of uncharacteristic breadth and diversity as compared to a lot of small biotechs,” Klemp said. “The typical small biotech has a primary technology and everything else orbits around it. We really have three distinctly different ones, and each one of them has blockbuster potential in our opinion.”

Leveraging Partnerships
Moleculin doesn't intend to wander far beyond candidate development, their CEO said. In fact, it expects to eventually bring its drugs to market with the help of strategic partners.

“A sales force is not necessarily out of the question, but our default position is: what we are good at is getting drugs from bench to clinic and generating real data,” Klemp said. “What big pharma is good at is navigating the labyrinth of payers and Phase 3 trials and the marketing undertaking, so our default position is we expect to partner with somebody once we’ve crossed the rubicon of demonstrating efficacy in humans.”

A Turning Point In Financing
As Moleculin nears that point, Klemp expects it to become more financially stable.

Before taking the company public, he got Moleculin off the ground with more than $13 million of his own money and friend-and-family financing. He brought it to market in summer 2016.

The stock is down 78.4 percent off its launch, but Klemp is not necessarily concerned.

“We know that when you initially go public, people have expectations of timelines and milestones, and if you look at the history of when we went public and then changes in the market and changes in our stock price, it’s consistent with us signaling to the market that the process of getting annamycin in clinics was going to take longer than originally expected,” he said.

“I don’t think it’s that surprising that, when that happens to a company, the stock price goes down, because people start to wonder, ‘is it going to happen when I wanted it to or not?’”

Klemp is convinced the company is at a “major turning point" as it prepares three clinical trials with subsequent data releases. It’s a turning point, he said, for both the stock and public sentiment.

As is usual in the biotech business, Moleculin has sustained operations through periodic offerings, most recently on Feb. 16.

“It’s a little bit of a chicken-and egg,” Klemp said. “When you make a new discovery and if it opens a new door for us, that gives us an opportunity sometimes to raise more capital, and that capital raise then gives us the latitude to add that to the development pipeline.”

Investors don’t always react kindly to the process. Moleculin shares dropped 26 percent after its last offering. Fortunately, clinical data could break the share dilution cycle, Klemp said.

Clinical data — particularly Phase 2 clinical trial data — typically marks a turning point where the next financing is either an exit "or a license that's tantamount to an exit," he said.

"At a minimum, the value of the company has responded to the clinical data enough so that the next financing is not nearly as diluted."

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 20 Mar 2018 19:04

Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery

HOUSTON, TX--(Marketwired - March 20, 2018) - Moleculin Biotech, Inc. (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has entered into a collaboration with a team of scientists in Poland who have received a $300,000 research grant to expand the understanding of how Moleculin's leading STAT3 inhibitor WP1066 and the Company's newly discovered drug candidate, WP1732, create a blockade of transcription factor STAT3 leading to tumor cell death and immune-stimulating effects.

"In parallel with our current clinical trial of WP1066 and our IND-enabling work on WP1732, we also want to increase our understanding of the molecular details of the mechanism by which these drug candidates have a demonstrated ability in preclinical testing to simultaneously attack tumors directly while also stimulating the immune system to fight cancer," commented Walter Klemp, Chairman and CEO of Moleculin. "The cutting-edge nature of our newly discovery drug candidates make it possible to attract non-dilutive research grant funding like this."

Moleculin has entered into a collaborative research agreement with Drs. Krzysztof Wozniak and Marcin Ziemniak of the University of Warsaw to explore the Company's STAT3 inhibitors using x-ray crystallography and other analytical methods to provide a more detailed understanding of how these compounds are able to affect what had previously been considered "undruggable" targets.
"Our grant funding has now enabled us to employ some of the best scientific methods available to research this important new discovery," added Prof. Wozniak. "We believe this class of molecules may represent one of the first known inhibitors that are able to potently affect the stability of key oncogenic transcriptional factors via a specific unique molecular process."
Dr. Ziemniak concluded, "Helping to explain how these remarkable compounds work may also additionally support their eventual approval as successful cancer drugs, which makes our basic research even that much more important."

About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.

For more information about the Company, please visit http://www.moleculin.com.
charel01 liked last!

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 21 Mar 2018 17:18

Bijgekocht.

isIT
Forum gebruiker
Forum gebruiker
Berichten: 199
Lid geworden op: 27 Jan 2012 14:18
waarderingen: 35
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor isIT » 21 Mar 2018 19:34

Eerste positie ingenomen...
Acacia Pharma Group, Geron Corporation, Johnson & Johnson, Neptune Wellness Solutions, TherapeuticsMD Inc, Transgene SA

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 27 Mar 2018 15:31

Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials
Patient enrollment for treatment has begun

HOUSTON, TX--(Marketwired - March 27, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered an agreement with The University Hospitals Cleveland Medical Center, which includes the Seidman Cancer Center and the Cleveland Clinic, to participate in its U.S. Phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and that patient enrollment has begun.

"This is an important milestone in establishing the efficacy of Annamycin in the treatment of AML in a U.S. trial," commented Walter Klemp, Chairman and CEO of Moleculin. "Coupled with the impending Annamycin clinical trial in Poland, we believe we are at an important inflection point to demonstrate the safety and effectiveness of our leading drug candidate. We have worked hard to get to this point, and we are gratified with the opportunities to move Annamycin forward."
alles kan beter liked last!

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 936
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 366
Contact:

MOLECULIN BIOTECH INC

Berichtdoor alles kan beter » 27 Mar 2018 17:28

ik zie niet meteen een topic over MOLECULIN BIOTECH INC..
nam onlangs kleine positie in. eerste nota sindsdien.


BRIEF-Moleculin Enters Agreement With Seidman Cancer Center To Conduct Leukemia Clinical Trials
14:37 (27/03) - Bron: RTRS
March 27 (Reuters) - Moleculin Biotech Inc :
* MOLECULIN ENTERS AGREEMENT WITH SEIDMAN CANCER CENTER TO
CONDUCT
LEUKEMIA CLINICAL TRIALS
charel01 liked last!
Just when you think you've hit rock bottom, someone will hand you a shovel.

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: MOLECULIN BIOTECH INC

Berichtdoor Munnybunny » 28 Mar 2018 08:02

Toch wel hoor. Ik heb op 12 maart een topic geopend ;)
Misschien beter daar verder te gaan waar ik al wat info gedeeld heb.
Beetje teleurstelling gisteren op de studie aankondiging. Eerst Polen en nu ook in de States.
neku liked last!

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 936
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 366
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor alles kan beter » 28 Mar 2018 18:08

Additionally, the Company announced potential
upcoming milestones and recent corporate developments.

Management Discussion
Walter Klemp, Chairman and CEO of Moleculin, said, "We continued to make
significant progress in developing Moleculin's distinctive cancer treatment
technologies during 2017. We firmly believe that all three of our highly
differentiated technologies have breakthrough potential in effectively
treating various cancers. From those three core technologies, we now have six
potential drug candidates, two of which we expect will commence clinical
trials in 2018, with the possibility of a third before the end of the year.

"Our potentially disruptive technologies include Annamycin, a chemotherapy
agent that is active against multidrug resistant tumor cells and has been
designed to be non-cardio toxic (unlike currently approved drugs in this
class); immuno-stimulating STAT3 inhibitors WP1066 and WP1732 that target
glioblastoma and pancreatic cancer; and WP1122, an inhibitor of glycolysis
that has been shown in preclinical testing to effectively block the energy
supply required by cancer cells and effectively starves the cancer cells to
death. Our diverse development portfolio gives Moleculin what I like to call
multiple shots on goal."

The Company submitted an application in October 2017 for a Clinical Trial
Authorization ("CTA") for Annamycin in Poland. Having met all the
requirements, the Ethics Committee in Poland approved the Phase I/II trial of
Annamycin for the treatment of relapsed or refractory acute myeloid leukemia
("AML") in December 2017. In March the Company received requests for and
provided additional information to the Polish National Office. It expects a
response from the Polish National Office in the first half of 2018 and at the
earliest mid-April 2018. The start of clinical trials in Poland remains
subject to confirmation and approval of the CTA by the Polish National Office.
The Company can provide no assurance that it will receive such confirmation on
a timely basis, if at all.

In addition, the Company continues to recruit and contract clinics both in the
United States and Poland. In the U.S., the Company has one site -- University
Hospitals Cleveland Medical Center ("UHCMC") -- recruiting patients and
enrollment has begun. The Company can provide no assurance that it will
continue enrollments or begin treatment on a timely basis, if at all.

Mr. Klemp continued, "Additionally, this past December we announced that a
physician-sponsored Investigational New Drug ("IND") application for a Phase I
trial of Moleculin's WP1066 in patients with recurrent malignant glioma and
brain metastasis from melanoma was allowed by the U.S. Food and Drug
Administration ("FDA"). This will be our second drug in clinical trials. The
trial will be conducted at the MD Anderson Cancer center to evaluate safety
and efficacy. We believe WP1066 represents a new class of oncology drugs able
to fight tumors on two fronts by directly inhibiting cell signaling supporting
tumor activity, and independently stimulating a natural immune response. This
constitutes a new approach to treating brain tumors and tumor metastasis to
the brain.

"We also intend to request a clinical trial authorization in Poland for WP1220
for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL), which we expect
will become our third compound in clinical trials in 2018. WP1220 is one of
our patented STAT3 inhibitors designed to be compatible with topical
formulations and was selected based on its preclinical activity in CTCL cell
lines and based on the need for better topical treatments for skin cancer.

"As we look ahead to 2019 and beyond, we are excited about a new molecule that
we recently licensed from MD Anderson -- WP1732 -- that shares many of the
same characteristics of WP1066, especially its ability to inhibit activated
STAT3, which is widely considered a key transcription factor involved in the
development and progression of tumors. WP1732 has demonstrated significantly
different organ distribution in animal models, suggesting it could be
especially well-suited to target systemic solid tumors including pancreatic
cancer, one of the most deadly and difficult to treat.

"An important attribute of WP1732 is that it is more water-soluble than
WP1066. So, while we have been focused on oral delivery of WP1066, WP1732 is
ideally suited to intravenous ("IV") administration, which makes the delivery
of the drug potentially more convenient and efficacious. We've already started
the process of preparing the preclinical data necessary for an IND for WP1732
and we hope to have that preparation completed in 2018.

"I also want to acknowledge the outstanding Scientific Advisory Board that is
part of the Moleculin brain trust. Waldemar Priebe, PhD., a Founder of
Moleculin and the Company's Founding Scientist, leads a team of world renown
experts in various cancer fields that includes John Paul Waymack, MD; Elihu
Estey, MD; and Jorge Cortes, MD. Together with our two Chief Medical Officers,
Robert Shepard, MD (Annamycin), and Sandra Silberman, MD (New Products), their
expertise and guidance have enabled us at Moleculin to successfully proceed in
the development of our highly differentiated compounds. Our expectation is
that 2018 will see significant progress in advancing our portfolio of unique
cancer treatments," concluded Mr. Klemp.

Fourth Quarter Highlights and Recent Corporate Developments
Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New
Discovery - March 20, 2018, the Company announced it has entered into a
collaboration with a team of scientists in Poland who have received a $300,000
research grant to expand the understanding of how Moleculin's leading STAT3
inhibitor WP1066 and the Company's newly discovered drug candidate, WP1732,
create a blockade of transcription factor STAT3 leading to tumor cell death
and immune-stimulating effects.

Moleculin Announces Pricing of $9 Million Registered Direct Offering -
February 16, 2018, the Company announced that it has entered into a definitive
agreement with institutional investors for a registered direct offering of
securities with gross proceeds of approximately $9 million.

Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer
Treatment - February 15, 2018, the Company announced that, pursuant to its
continued collaboration with MD Anderson it has developed and licensed what it
believes, based on preclinical testing, is a major breakthrough in its effort
to develop a new cancer treatment that selectively kills highly resistant
tumors. Specifically, the Company has preclinical evidence to suggest it is
capable of influencing a process known as 'ubiquitination' to block the
activated form of STAT3, an important oncogenic transcription factor. The lead
molecule resulting from this new discovery is called WP1732 and it not only
appears to share the same key mechanistic properties with WP1066, it has
markedly different organ distribution and its dramatically increased
solubility makes it ideal for administration via standard IV injection.
Importantly, preclinical testing has also shown that WP1732's properties make
it a promising candidate for treating pancreatic cancer.

Moleculin Announces Collaboration with Emory University to Develop Novel
Treatment of Pediatric Brain Cancer - February 13, 2018, the Company announced
it has entered into an agreement with Emory University to enable expanded
cancer research on Moleculin's WP1066 molecule for the possible treatment of
medulloblastoma, a pediatric malignant primary brain tumor.
Physician-scientists at Emory University and Children's Healthcare of Atlanta
have requested support to continue research aimed at the development of a
novel treatment of medulloblastoma using WP1066 and Moleculin has agreed to
supply them with a pure form of WP1066 for preclinical testing for the
potential future treatment of patients with the disease. Emory studies so far
have indicated that medulloblastoma may be particularly vulnerable to the
ability of WP1066 to block the activated form of STAT3, a key signaling
protein believed to contribute to the growth and survival of many tumors,
including medulloblastoma.

Moleculin Announces Activity with Pancreatic Cancer Drug - February 7, 2018,
the Company announced it has been able to show promising tumor suppression
activity with its inhibitor of glycolysis, WP1122. The Company's glycolysis
inhibitors have shown a remarkable affinity for concentrating in the pancreas
and has solid data showing the ability of WP1122 to inhibit pancreatic tumor
growth in mice.

Leading Leukemia Experts Join Moleculin's Science Advisory Board - January 17,
2018, the Company announced the expansion of its Science Advisory Board to
include Drs. Jorge Cortes and Elihu Estey.

Jorge Cortes, M.D., is deputy chair and professor of medicine in the
Department of Leukemia at MD Anderson Cancer Center where he directs the CML
and AML Programs. Dr. Cortes received his medical degree in 1986 from the
Universidad Nacional Autonoma de Mexico, and has been at MD Anderson since
1991. Dr. Cortes, whose clinical interest focuses on new drug development and
the management of patients with myelodysplatic syndromes, acute and chronic
leukemias, and myeloproliferative disorders, has authored over 900
peer-reviewed medical publications in top-tier journals including New England
Journal of Medicine, Lancet Oncology, Lancet Hematology, Journal of Clinical
Oncology, Leukemia, Blood and many others.

Elihu Estey, M.D., is a Professor of Medicine in the Division of Hematology at
the University of Washington School of Medicine and a Full Member and Director
of AML Clinical Research (non-transplant) Clinical Research Division, Fred
Hutchinson Cancer Research Center. Dr. Estey has built a distinguished career
in cancer research approaching 40 years of active clinical practice with AML
patients, providing mentorships for many physicians that have risen to
prominence in AML, lectured globally to professional audiences on cancer
research and published more than 700 articles on hematologic malignancies,
specifically on AML. Additionally, Dr. Estey serves on the European Leukemia
Net (ELN) guidelines committee for AML and has served as an advisor for AML
studies to the Oncology Drugs Advisory Committee ("ODAC") of the FDA.

Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3
Inhibitor - January 10, 2018, the Company announced it has expanded the
Company's development pipeline for the treatment of AML with an
immuno-stimulating STAT3 inhibitor. Leading experts in the treatment of AML,
Dr. Jorge Cortes and Dr. Sanjay Awasthi requested the Company to expand its
clinical research to include WP1066, an immuno-stimulating agent and STAT3
inhibitor, to increase therapeutic options for AML patients. This would
potentially be complementary and synergistic with Annamycin and existing first
line treatments.

Moleculin Announces Polish Approval for Leukemia Clinical Trial - December 21,
2017, the Company announced that the Ethics Committee in Poland has approved
the Company's Phase I/II clinical trial of Annamycin for the treatment of
relapsed or refractory AML.

Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance - December 5, 2017,
the Company announced the physician-sponsored IND application for a Phase I
trial of Moleculin's drug WP1066 in patients with recurrent malignant glioma
and brain metastasis from melanoma has been allowed by the FDA. WP1066 is the
second of Moleculin's drugs to enter clinical stage and represents a new class
of oncology drugs able to fight tumors on two fronts by directly inhibiting
cell signaling and independently stimulating a natural immune response. This
IND was sponsored by Dr. Amy Heimberger, who will serve as the principal
investigator for the Phase I trial at MD Anderson Cancer Center to evaluate
safety and efficacy.

Moleculin Appoints Dr. Sandra Silberman as Chief Medical Officer - New
Products - November 8, 2017, the Company announced the appointment of Dr.
Sandra Silberman as Chief Medical Officer ("CMO") in charge of New Products.

Moleculin Announces MD Anderson has Filed an IND with the FDA on its Drug
WP1066 for the Treatment of Brain Tumors - November 1, 2017, the Company
announced that responses have been submitted to FDA requests for additional
information relating to the physician-sponsored IND application to study
WP1066 as a potential treatment for brain tumors.

Moleculin Requests Authorization from the Polish Government to Advance
Annamycin - October 24, 2017, the Company announced that it has submitted its
request for CTA in Poland which, if allowed, will enable a clinical trial to
study Annamycin for the treatment of relapsed or refractory AML in Poland.
This will be in addition to the previously announced allowance of Moleculin's
IND filing with the FDA.

Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in
Annamycin Trial - October 18, 2017, the Company announced that 14 qualified
cancer clinics have requested to participate in its clinical trial to study
Annamycin for the treatment of relapsed or refractory AML.

Moleculin Announces Strategic Collaboration to Develop Immuno-stimulating Drug
- October 11, 2017, the Company announced that it has entered into an
agreement to collaborate with the University of Bergen to expand research on
WP1066 and early indications of a possible dual ability to increase immune
system response to tumors while also suppressing tumor cell proliferation
tumor cell and survival.

Moleculin Signs Agreement with First Hospital for Annamycin Trials - October
3, 2017, the Company announced it has entered into an agreement with the first
of several hospitals desiring to become treatment sites for its clinical trial
to study Annamycin for the treatment of relapsed or refractory AML.

Moleculin Announces FDA Approval of Annamycin IND - September 26, 2017, the
Company announced that the FDA has allowed Moleculin's IND for the study of
Annamycin in relapsed or refractory AML to proceed. This allows Moleculin to
begin clinical trials of Annamycin in the U.S.

Anticipated Milestone Potential Timeframe
Announcement that our IND for Annamycin has become effective and that we may begin clinical trials Accomplished
Initial IRB (Institutional Review Board) approvals and site initiations of various clinical sites participating in our Phase I/II clinical trial of Annamycin Accomplished and ongoing through Second Half of 2018
Establishment of a new RP2D for Annamycin Second Half of 2018
A clinician sponsored IND for WP1066 for treatment of adult brain tumors moving forward IND Accomplished ; Trial expected to begin First Half of 2018
Announcement of initial Clinical Data for Annamycin trial 2018
Announcement of further benefits of our sponsored research agreement with MD Anderson Accomplished and Ongoing into 2019
Announce CTA for WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL) 2018
Announce WP1122 and WP1732 move into preclinical work 2018
Announce the fourth drug approved for clinical trial 2019
Just when you think you've hit rock bottom, someone will hand you a shovel.